Table 1_Immune-inflammation index as prognostic markers in metastatic castration-resistant

A systematic review and meta-analysis of 36 studies involving 10,325 patients with metastatic castration-resistant prostate cancer (mCRPC). The document, authored by Zitong Qin and last updated in April 2026, synthesizes evidence on the association between blood-derived immune-inflammatory indices and survival outcomes.

Use Cases

• Assessing the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) for overall survival (OS) and progression-free survival (PFS) in mCRPC.
• Evaluating the platelet-to-lymphocyte ratio (PLR) as a predictor of survival outcomes in metastatic prostate cancer.
• Investigating the relationship between the systemic immune-inflammation index (SII) and worse OS in mCRPC patients.
• Analyzing the lymphocyte-to-monocyte ratio (LMR) for its association with improved OS in mCRPC.

Strengths

• Analysis is based on 36 studies and 10,325 patient records, providing a substantial evidence base.
• Follows PRISMA 2020 guidelines and is registered in PROSPERO (CRD420261291003), indicating a structured methodology.
• Reports pooled hazard ratios with 95% confidence intervals for multiple immune-inflammatory indices (NLR, PLR, SII, LMR).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is a 17.7 KB DOCX file, indicating a limited scope focused on the review's textual results and tables.

Provenance

Source

figshare

Collection Method

Systematic review and meta-analysis of studies from Embase, PubMed, Web of Science, and the Cochrane Library queried from inception until May 2025.

Time Range

Studies included from database inception until May 2025.

Freshness

Last updated 2026-04-27 04:14:40; freshness should be verified.

Geography

null